ArticleCureus2025
Cost-Effective Markers for Identifying Poor Glycemic Control in Type 2 Diabetes Mellitus: The Role of the Triglyceride-Glucose Index.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Insulin resistance is a major risk factor for type 2 diabetes mellitus (T2DM), contributing to poor glycemic control and diabetic complications. This study aimed to investigate the correlation of the triglyceride-glucose (TyG) index, TyG-BMI index, and TG/HDL ratio with glycemic control. Methods A cross-sectional study was conducted from October 2023 to February 2024 at the Jericho Health Center, Palestine. A total of 240 T2DM patients were categorized into two groups based on glycemic control: good (HbA1c <7) and poor (HbA1c ≥7). Spearman correlation was used to assess the associations, and receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive performance of the indices. Results Of 240 patients, 39% had good and 61% had poor glycemic control. The TyG and TyG-BMI indices were significantly higher (P<0.001) in those with poor glycemic control (5.0 vs. 4.8; 155 vs. 142, respectively). The TyG index cutoff was 4.8 (81% sensitivity, 55% specificity; AUC=0.744, p<0.001) while the TyG-BMI index cutoff was 162 (43.2% sensitivity, 76.3% specificity; AUC=0.591, p=0.018). The TyG index correlated positively with fasting plasma glucose (r=0.687), HbA1c (r=0.464), triglycerides (r=0.740), and cholesterol (r=0.254), and negatively with HDL-C (r=-0.200; all p<0.01). TyG-BMI correlated strongly with BMI (r=0.939) and weakly but significantly with systolic (r=0.204) and diastolic blood pressure (r=0.146). No significant correlation was found between TG/HDL and glycemic control. Conclusion Compared to TyG-BMI, the TyG index showed better diagnostic accuracy and stronger associations with metabolic markers, suggesting it may serve as a cost-effective and practical marker for evaluating glycemic control in T2DM patients. The low area under the curve (AUC) and sensitivity of TyG-BMI might limit its usefulness in this context. Establishing a population-specific cutoff based on inexpensive and routine laboratory measures enhances its practical utility in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.